13D Filings
ESSA Pharma Inc.
Amendment
Ownership

24.70%

Total Shares

11,668,473

Issuer CIK

1633932

CUSIP

29668H708

Event Date

Aug 4, 2025

Accepted

Aug 7, 2025, 04:31 PM

Reporting Persons (10)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
BVF PARTNERS L P/IL
Investment Adviser
24.70%11,668,473011,668,473
LAMPERT MARK N
Individual
24.70%11,668,473011,668,473
BVF INC/IL
CO
24.70%11,668,473011,668,473
BVF GP HOLDINGS LLC
Other
23.10%10,920,888010,920,888
BIOTECHNOLOGY VALUE FUND L P
Partnership
13.10%6,194,14506,194,145
BVF I GP LLC
Other
13.10%6,194,14506,194,145
BVF II GP LLC
Other
9.99%4,726,74304,726,743
BIOTECHNOLOGY VALUE FUND II LP
Partnership
9.99%4,726,74304,726,743
BVF Partners OS Ltd.
CO
1.20%560,7970560,797
Biotechnology Value Trading Fund OS LP
Partnership
1.20%560,7970560,797
Disclosure Items (6)

Security Title

Common Shares

Issuer Name

ESSA Pharma Inc.

Issuer Address

SUITE 720, VANCOUVER, A1, V5Z 1K5

Item 3 is hereby amended and restated to read as follows: The securities of the Issuer purchased by each of BVF, BVF2 and Trading Fund OS, and held in the Partners Managed Account, were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 6,194,145 Common Shares (the "Shares") owned directly by BVF is approximately $22,714,817, including brokerage commissions. The aggregate purchase price of the 4,726,743 Shares owned directly by BVF2 is approximately $16,575,234, including brokerage commissions. The aggregate purchase price of the 560,797 Shares owned directly by Trading Fund OS is approximately $1,779,975, including brokerage commissions. The aggregate purchase price of the 186,788 Shares held in the Partners Managed Account is approximately $1,292,828, including brokerage commissions.

Item 4 is hereby amended to add the following: On August 5, 2025, certain of the Reporting Persons including BVF, BVF2 and Trading Fund OS entered into a waiver and agreement to exercise (the "Waiver and Agreement") with the Issuer with respect to the amended and restated common share purchase warrants (the "Pre-Funded Warrants") held by them in connection with the Issuer's proposed upcoming merger. Pursuant to the Waiver and Agreement, (i) BVF, BVF2, Trading Fund OS and the Issuer agreed to waive the 19.99% beneficial ownership limitation set forth in Section 2(e) of the Pre-Funded Warrants to permit the full exercise of the of the Pre-Funded Warrants held by them, and (ii) BVF, BVF2 and Trading Fund OS exercised all of the Pre-Funded Warrants held by them in a cashless exercise to acquire 1,481,555 Shares, 1,234,964 Shares and 203,325 Shares, respectively, effective August 5, 2025 (the "Exercise"). A copy of the Waiver and Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Percentage of Class

Item 5(a) is hereby amended and restated to read as follows: The aggregate percentage of Shares reported owned by each person named herein is based upon a denominator that is the sum of (i) 44,388,550 Shares outstanding, which is the total number of Shares expected to be outstanding as of August 5, 2025 as reported in the Issuer's Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on July 30, 2025, and (ii) 2,919,844 Shares acquired by certain of the Reporting Persons in connection with the cashless exercise of the Pre-Funded Warrants described in further detail in Item 4 above. As of the date hereof, (i) BVF beneficially owned 6,194,145 Shares, representing percentage ownership of approximately 13.1% of the Shares outstanding, (ii) BVF2 beneficially owned 4,726,743 Shares, representing percentage ownership of approximately 9.99% of the Shares outstanding, (iii) Trading Fund OS beneficially owned 560,797 Shares, representing percentage ownership of approximately 1.2% of the Shares outstanding, and (iv) 186,788 Shares were held in the Partners Managed Account, representing percentage ownership of less than 1% of the Shares outstanding. BVF GP, as the general partner of BVF, may be deemed to beneficially own the 6,194,145 Shares beneficially owned by BVF, representing percentage ownership of approximately 13.1% of the Shares outstanding. BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 4,726,743 Shares beneficially owned by BVF2, representing percentage ownership of approximately 9.99% of the Shares outstanding. Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 560,797 Shares beneficially owned by Trading Fund OS, representing percentage ownership of approximately 1.2% of the Shares outstanding. BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 10,920,888 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 23.1% of the Shares outstanding. Partners, as the investment manager of BVF, BVF2, Trading Fund OS and the Partners Managed Account and the sole member of Partners OS, may be deemed to beneficially own the 11,668,473 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and held in the Partners Managed Account, representing percentage ownership of approximately 24.7% of the Shares outstanding. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 11,668,473 Shares beneficially owned by Partners, representing percentage ownership of approximately 24.7% of the Shares outstanding. Mr. Lampert, as the sole director and officer of BVF Inc., may be deemed to beneficially own the 11,668,473 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 24.7% of the Shares outstanding. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account.

Transactions

Item 5(c) is hereby amended and restated to read as follows: Other than as set forth in Item 4 above and in the immediately following sentence, there were no transactions in the securities of the Issuer by the Reporting Persons during the past sixty days. In connection with the Exercise, BVF, BVF2 and Trading Fund OS disposed of 70, 66, and 11 Shares to the Issuer, respectively, based on a market price of $1.8779 per Share.

Item 6 is hereby amended to add the following: On August 5, 2025, BVF, BVF2 and Trading Fund OS entered into the Waiver and Agreement with the Issuer as described in Item 4 above. A copy of the Waiver and Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 7 is hereby amended to add the following exhibit: 99.1 - Waiver and Agreement, dated August 5, 2025.

ESSA Pharma Inc. — Schedule 13D | 13D Filings